Biontech Announces Strategic Transaction To Acquire Curevac In Public Exchange Offer

June 12 (Reuters) - BIONTECH SE 22UAy.DE:

• BIONTECH ANNOUNCES STRATEGIC TRANSACTION TO ACQUIRE CUREVAC IN PUBLIC EXCHANGE OFFER

• PUBLIC EXCHANGE OFFER FOR ALL SHARES OF CUREVAC WHERE EACH SHARE OF CUREVAC WILL BE EXCHANGED FOR APPROX. $5.46 IN BIONTECH AMERICAN DEPOSITARY SHARES

• IMPLIED AGGREGATE EQUITY VALUE FOR CUREVAC OF APPROX. $1.25 BILLION

• EXPECTED TO CLOSE IN 2025

• TRANSACTION WAS UNANIMOUSLY APPROVED BY BOTH BIONTECH'S AND CUREVAC'S MANAGEMENT AND SUPERVISORY BOARDS

• CUREVAC SHAREHOLDERS TO OWN 4%-6% OF BIONTECH POST-DEAL

• SHAREHOLDERS REPRESENTING 36.76% OF CUREVAC SHARES ENTER TENDER AGREEMENTS

Further company coverage: 22UAy.DE